Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.

16. november 2026 oppdatert av: Immuneering Corporation

A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants

Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Aged 18 years or older
  • Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or metastatic disease. Prior adjuvant or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence.
  • Measurable disease (at least 1 target lesion) per RECIST 1.1.
  • ECOG performance status of 0 or 1.
  • PD-L1 score determined by an FDA-approved test.
  • RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid biopsy is acceptable.
  • Adequate organ function:

Exclusion Criteria:

  • Inability to swallow oral medications.
  • EGFR, ALK or ROS1 mutation.
  • Untreated or unresolved brain metastases
  • Encephalitis, meningitis or uncontrolled seizures in the year before informed consent.
  • History of interstitial lung disease non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids, or any pneumonitis within the last 5 years. Radiation pneumonitis in the radiation field is permitted.
  • Active autoimmune disease that required systemic treatment in the past 12 months.
  • A condition requiring corticosteroids >10 mg/day prednisone or equivalent within 14 days of Cycle 1 Day 1.
  • Prior allogeneic tissue or solid organ transplant.
  • Never-smoker (fewer than 100 cigarettes in a lifetime).
  • Prior anti-PD-1 or anti-PD-L1 therapy.
  • Impaired cardiac function or clinically significant cardiac disease, including left ventricular ejection fraction <50% by ECHO or MUGA or screening QTcF >470 msec.
  • History of serous retinopathy, retinal edema or retinal pigment epithelial detachment.
  • History or current evidence of retinal vein occlusion (RVO), or current RVO risk factors.
  • Rhabdomyolysis within 3 months before Study Day 1.
  • Major surgery or significant traumatic injury within 4 weeks before the first dose.
  • Another malignancy.
  • Any infection requiring hospitalization or IV anti-infectives within 2 weeks before the first dose.
  • Uncontrolled HIV, hepatitis B or hepatitis C infection; immunodeficiency; or active or latent tuberculosis.
  • Live vaccine within 4 weeks before the first dose.
  • COVID-19 vaccination within 1 week before the planned first dose, or a planned COVID-19 vaccination series that won't be completed at least 1 week before the first dose.
  • Known hypersensitivity to any study drug or excipient.
  • Unwillingness to use effective contraception

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Atebimetinib + Cemiplimab ± Chemotherapy

Participants receive atebimetinib orally once daily (160, 240 or 320 mg) plus cemiplimab 350 mg IV every 3 weeks. Carboplatin and pemetrexed are given IV every 3 weeks for 4 cycles in the dose optimization portion, and in the expansion portion for participants with PD-L1 <50%. The expansion uses the atebimetinib dose selected during dose optimization.

Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg

Andre navn:
  • IMM-1-104

Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks

Andre navn:
  • REGN2810
  • Libtayo

AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4

500 mg/m² IV on Day 1 of Cycles 1-4

Andre navn:
  • Alimta

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of Atebimetinib
Tidsramme: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.

Measured in dose optimization

Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
Objective Response Rate (ORR)
Tidsramme: Every 8 weeks, up to approximately 24 months

Percentage of participants with complete or partial response per RECIST 1.1

Every 8 weeks, up to approximately 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Median Progression-Free Survival (PFS)
Tidsramme: Up to approximately 24 months.

Time from Cycle 1 Day 1 to first documented disease progression per RECIST v1.1 or death from any cause, whichever comes first.

Up to approximately 24 months.
Overall Survival (OS)
Tidsramme: From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.

Time from Cycle 1 Day 1 to death from any cause.

From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
Number of Participants with adverse events
Tidsramme: From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.

Treatment-emergent and treatment-related AEs per CTCAE v6.0

From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Vinny Hayreh, Immuneering Corporation

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. mai 2029

Studiet fullført (Antatt)

1. juli 2029

Datoer for studieregistrering

Først innsendt

6. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere